Dovato (dolutegravir/lamivudine) / ViiV Healthcare - LARVOL DELTA

A model-based comparison of dose reduction strategies for fixed-dose dolutegravir-containing regimens. (PubMed, J Antimicrob Chemother) - "Safety and effectiveness of TLD dose reduction strategies can only be established in clinical studies and cannot be extrapolated from models. However, these models can inform regimen design to limit the window of opportunity for emergence of resistance, i.e. where viral replication occurs in the presence of appreciable drug concentrations."

Journal

Safety and Efficacy of Dolutegravir/Lamivudine (DTG/3TC) in Therapy-naive Human Immunodeficiency Virus-1 (HIV-1) Infected Adolescents (clinicaltrials.gov) - P3 | N=32 | Completed | Sponsor: ViiV Healthcare | Active, not recruiting ➔ Completed | Trial completion date: Sep 2024 ➔ May 2025

Trial completion • Trial completion date • Human Immunodeficiency Virus • Infectious Disease

Clarifying INSTINCT: Switching from DTG/3TC to BIC/FTC/TAF Shows Comparable Inflammatory and Weight Outcomes. (PubMed, Clin Infect Dis) - No abstract available

Journal

Toxoplasmic encephalitis unmasked during treatment for miliary tuberculosis in a patient with human immunodeficiency virus infection: a case report and literature review. (PubMed, Trop Med Health) - "TE can emerge during immune recovery at CD4 counts > 100 cells/µL when corticosteroid administration coincides with early ART. In patients receiving tuberculosis treatment who develop new brain lesions soon after ART, T. gondii polymerase chain reaction and prompt antiparasitic therapy should be pursued. Rifabutin permits concomitant use of dolutegravir, and TMP-SMX desensitization allows effective treatment and prophylaxis."

Journal • CNS Disorders • Human Immunodeficiency Virus • Infectious Disease • Pain • Pulmonary Disease • Respiratory Diseases • Tuberculosis • CD4

Enhanced immune recovery with B/F/TAF compared with DTG/3TC in HIV patients: A prospective observational study. (PubMed, J Infect Public Health) - "These findings underscore the clinical advantages of the B/F/TAF regimen in promoting immune reconstitution among HIV patients. Future studies should investigate whether the observed differences in immune recovery translate into reduced morbidity and mortality rates over time."

Journal • Observational data • Human Immunodeficiency Virus • Infectious Disease • CD4

A Comparison of the Risk of Viral Load Blips in Human Immunodeficiency Virus Patients on Two-Drug Versus Three-Drug Antiretroviral Regimens. (PubMed, Infect Dis Rep) - " A total of 121 patients were included, with 44 receiving two-drug regimens (e.g., dolutegravir/lamivudine) and 77 receiving three-drug regimens (e.g., bictegravir/tenofovir alafenamide/emtricitabine) at the time of analysis. No virologic failure was observed. These findings suggest that two-drug regimens provide virologic control comparable to three-drug regimens and may be a viable clinical option due to fewer drug interactions, lower toxicity, and reduced cost."

Journal • Human Immunodeficiency Virus • Infectious Disease

Prevalence and risk factors of adverse drug events with dolutegravir-based regimens among Thai people living with HIV: a retrospective cohort study. (PubMed, AIDS Res Ther) - "Over half (53.86%) of patients on long-term DTG-based therapy experienced at least one ADE. Risk was significantly elevated in older adults, those with psychiatric illness, previous cryptococcosis, underweight status, or lower baseline eGFR. Healthcare providers should implement proactive monitoring and tailored management strategies for these high-risk patients to optimize ART safety and efficacy outcomes."

Adverse events • Journal • Retrospective data • Hematological Disorders • Human Immunodeficiency Virus • Infectious Disease • Mental Retardation • Psychiatry

Comparative Safety of B/F/TAF vs. Other Antiretroviral Therapy Regimens for Treatment-Experienced People With HIV-1: A Systematic Literature Review and Indirect Comparisons Using Multilevel Network Meta-Regression (ISPOR-EU 2025) - "Compared to B/F/TAF, ML-NMR results showed significantly greater decline in eGFR from baseline with dolutegravir/lamivudine (DTG/3TC) (mean difference [95% CrI]: -4.40 [-5.30, -3.51]) and DTG/abacavir/3TC (-3.60 [-5.74, -1.50]); change in eGFR was similar to DTG+F/TAF (-1.19 [-3.35, 1.06]). B/F/TAF demonstrated a more favorable renal safety profile compared to tenofovir-sparing DTG-based regimens, with similar all-cause discontinuation rates compared to other recommended ARTs, including DTG/3TC, and the investigational NRTI-sparing doravirine/islatravir. These findings support B/F/TAF as a renally safe and well-tolerated treatment option for TE PWH."

Clinical • Review • Human Immunodeficiency Virus • Infectious Disease

Two or Three? Clinical and Proteomic Perspectives on Dolutegravir/Lamivudine Versus Bictegravir/Emtricitabine/Tenofovir Alafenamide as Initial HIV Treatment. (PubMed, Open Forum Infect Dis) - "Despite being used in patients with more advanced profiles, BIC/F/TAF effectively reduced systemic inflammation over 2 years. Both regimens attenuated inflammatory activity, though with distinct trajectories that may carry implications for immune recovery and long-term outcomes."

Clinical • Journal • Human Immunodeficiency Virus • Infectious Disease • Inflammation • CD4

Management of HIV-related Progressive Multifocal Leukoencephalopathy: insights from metagenomic next-generation diagnosis and pembrolizumab-lenalidomide therapy, a case report (EACS 2025) - "The individual received intensified cART (dolutegravir, lamivudine, zidovudine, albuvirtide), a 21-day course of lenalidomide (25 mg/day), and four pembrolizumab infusions (100 mg/dose). This case emphasizes the diagnostic value of brain tissue mNGS for PML when CSF testing is inconclusive. The pembrolizumab-lenalidomide regimen showed tolerability and potential efficacy in restoring anti-JCV immunity, supported by improved clinical outcomes and immune markers. However, long-term benefits and mechanisms require validation in larger cohorts."

Case report • Clinical • IO biomarker • Human Immunodeficiency Virus • Infectious Disease • CD4 • CXCL8 • IL6

When the Therapy Bites Back: Drug-Induced Necrotizing Pancreatitis in an HIV Positive Patient (ACG 2025) - "Two months prior to admission, the patient's antiretroviral therapy had been switched from dolutegravir/lamivudine to DRV/COBI/FTC/TAF due to weight gain. Drug-induced pancreatitis was determined to be the cause of severe necrotizing pancreatitis in our patient after other causes were ruled out. As novel antiretroviral therapies emerge, HIV positive patients should be closely monitored for rare complications following initiation or modification of therapy."

Clinical • CNS Disorders • Dyslipidemia • Gastroenterology • Hepatology • Human Immunodeficiency Virus • Hypertriglyceridemia • Infectious Disease • Pancreatitis • Septic Shock

A Multi-center Randomized Clinical Trial on BIC/FTC/TAF vs DTG+3TC+TDF in People with HIV Who Experience Virologic Failure in China (ChiCTR) - P=N/A | N=374 | Recruiting | Sponsor: Beijing Youan Hospital, Capital Medical University; Beijing Youan Hospital, Capital Medical University

New trial • Human Immunodeficiency Virus • Infectious Disease

A Quality Improvement Pilot to Increase Hepatitis B Screening and Optimize Patient Selection for the Switch to Two-Drug Antiretroviral Regimens in People With HIV. (PubMed, Open Forum Infect Dis) - "An EHR best practice advisory was linked to 2DR orders (dolutegravir-lamivudine, dolutegravir-rilpivirine, cabotegravir-rilpivirine) reminding clinicians to check HBV serologies prior to the switch and providing guidance for prescribing 2DRs to reduce risk of HBV reactivation in people with HIV. In this study, an EHR-based intervention increased HBV screening rates and decreased switches in those at highest risk of HBV reactivation (positive HBsAg or isolated positive HBcAb). With the increasing uptake of 2DRs, optimizing patient selection is vital to prevent HBV reactivation."

Journal • Hepatitis B • Human Immunodeficiency Virus • Infectious Disease • Inflammation

Real-World Persistence in Adults with HIV and Mental Health or Substance Use Disorders After Restarting Antiretroviral Therapy in the United States. (PubMed, Adv Ther) - "For PWH-MHD/SUD who restarted ART after a treatment interruption, B/F/TAF was associated with longer persistence and the lowest risk of switch compared with other guideline-recommended therapies."

Journal • Real-world evidence • CNS Disorders • Human Immunodeficiency Virus • Infectious Disease • Psychiatry

Patient-reported outcomes among people living with HIV switching to dual therapy with dolutegravir/lamivudine: results from the PROBI study. (PubMed, Ther Adv Infect Dis) - P=N/A | "Men, individuals previously receiving abacavir/3TC/DTG, and those with better daily comfort and perceived treatment efficacy were less likely to stop treatment. Attention should be maintained on the reasons for treatment discontinuation, especially among women. Patient-Reported Outcomes HV BItherapy (PROBI) was registered as number NCT04788784 on https://clinicaltrials.gov/study/NCT04788784?term=PROBI&rank=2."

Journal • Human Immunodeficiency Virus • Infectious Disease

Virological non-inferiority and lower weight gain with DTG/3TC versus BIC/FTC/TAF: 96-week final results from the PASO-DOBLE (GeSIDA 11720) randomised, multicentre, open-label, non-inferiority trial (EACS 2025) - P4 | "Weight gain >5% was associated with a worse lipid profile ( Table 2 ). Conclusions : DTG/3TC demonstrated non-inferior virological efficacy and a better metabolic profile than BIC/FTC/TAF, supporting its use as a switch option."

Clinical • Head-to-Head • Late-breaking abstract • Human Immunodeficiency Virus • Infectious Disease

Multicenter Real-World Study on the Effectiveness of Dolutegravir Plus Lamivudine in Treatment-Naïve People Living with HIV with Baseline Plasma HIV-1 RNA >500,000 Copies/mL [WITHDRAWN] (EACS 2025) - No abstract available

Clinical • Late-breaking abstract • Real-world • Real-world evidence • Human Immunodeficiency Virus • Infectious Disease

48-WEEK RESULTS OF SWITCHING FROM DTG/3TC TO BIC/FTC/TAF IN PWH AND NEUROPSYCHIATRIC COMORBIDITIES (EACS 2025) - "Our study was not designed to evaluate potential differences between starting ART or switching to these two regimens. Further studies are needed to answer that question in this population."

Human Immunodeficiency Virus • Infectious Disease

Changes in cardiovascular and metabolic risk scores after switching to DOR/3TC/TDF, DTG/3TC or BIC/FTC/TAF: results from a multicenter Italian cohort (EACS 2025) - "Finally, regarding METS-IR, after 48 weeks we observed a significant decrease in the DOR group (-0.9, p=0.024), while there were no significant changes with DTG and an increase of +0.3 with BIC (p=0.013). Conclusions : We found that switching to DOR/3TC/TDF was associated with more favorable changes in SCORE-2, METS-IR and BMI compared to DTG/3TC and BIC/FTC/TAF."

Clinical • Infectious Disease

Switching to dolutegravir/lamivudine is non-inferior to continuing triple-drug ART in virologically suppressed people with HIV: 2 year results of the DUALING prospective matched nationwide clinical practice study (EACS 2025) - "In post-hoc analysis, discontinuing tenofovir-based triple drug ART led to weight gain in people with (2.7kg) and without (2.3kg) prior dolutegravir use. Conclusions : In this nationwide clinical practice study, switching to dolutegravir/lamivudine was non-inferior to continuing triple-drug ART in people with HIV after 2 years of follow-up."

Clinical • Human Immunodeficiency Virus • Infectious Disease • CD4

“Leaving no stones unturned”: 10 years results on the tolerability and metabolic safety of DTG+3TC as a switch regimen (EACS 2025) - "Two pregnancies continued during therapy, both without complications. Conclusions : In the long-term, switching to DTG+3TC was well tolerated, with significant improvement in metabolic parameters."

Clinical • Human Immunodeficiency Virus • Infectious Disease • CD4

MeP19 - Beyond with DTG/3TC (EACS 2025) - "ePoster Station 3"

Infectious Disease

Evolution of Proviral DNA M184V/I Over 96 Weeks Does Not Predict Virologic Failure of Dolutegravir/Lamivudine in the VOLVER Trial (EACS 2025) - "The observed increase in M184V/I frequency over time appears to have no clinical consequence. These findings reinforce the lack of clinical utility of proviral-DNA resistance testing to guide treatment decisions in virologically suppressed PWH with prior M184V/I"

Human Immunodeficiency Virus • Infectious Disease

The Power of Choice: Perspectives From Healthcare Providers on Early Switch to CAB+RPV LA After Rapid Suppression With DTG/3TC (EACS 2025) - "Conclusions : SSPs want to empower PWH with the choice for early switch to CAB+RPV LA immediately following suppression. This approach is perceived positively, providing benefits such as reduced medication burden, while addressing concerns around daily pill intake, stress/anxiety around adherence, and disclosure of HIV status."

Human Immunodeficiency Virus • Infectious Disease

Use of PCSK9 inhibitor evolocumab in PLWH with persistent hyperlipidemia despite statin therapy: two case reports (EACS 2025) - "A 59 years-old male in treatment with DTG/3TC was in lipid-lowering tratment with rosuvastatin/ezetimibe 40/10mg...Its lipid-lowering effects, combined with a favorable tolerability profile, suggest a potential role in reducing cardiovascular risk in this population. Further large-scale, long-term studies are needed to confirm its impact on clinical outcomes and interactions in the context of ART."

Case report • Clinical • Human Immunodeficiency Virus • Infectious Disease